61 research outputs found
Interleukin-1 beta and neurotrophin-3 synergistically promote neurite growth in vitro
Pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) are considered to exert detrimental effects during brain trauma and in neurodegenerative disorders. Consistently, it has been demonstrated that IL-1β suppresses neurotrophin-mediated neuronal cell survival rendering neurons vulnerable to degeneration. Since neurotrophins are also well known to strongly influence axonal plasticity, we investigated here whether IL-1β has a similar negative impact on neurite growth. We analyzed neurite density and length of organotypic brain and spinal cord slice cultures under the influence of the neurotrophins NGF, BDNF, NT-3 and NT-4. In brain slices, only NT-3 significantly promoted neurite density and length. Surprisingly, a similar increase of neurite growth was induced by IL-1β. Additionally, both factors increased the number of brain slices displaying maximal neurite growth. Furthermore, the co-administration of IL-1β and NT-3 significantly increased the number of brain slices displaying maximal neurite growth compared to single treatments. These data indicate that these two factors synergistically stimulate two distinct aspects of neurite outgrowth, namely neurite density and neurite length from acute organotypic brain slices
Intrathecal heat shock protein 60 mediates neurodegeneration and demyelination in the CNS through a TLR4- and MyD88-dependent pathway
Background Toll-like receptors (TLR) constitute a highly conserved class of
receptors through which the innate immune system responds to both pathogen-
and host-derived factors. Although TLRs are involved in a wide range of
central nervous system (CNS) disorders including neurodegenerative diseases,
the molecular events leading from CNS injury to activation of these innate
immune receptors remain elusive. The stress protein heat shock protein 60
(HSP60) released from injured cells is considered an endogenous danger signal
of the immune system. In this context, the main objective of the present study
was to investigate the impact of extracellular HSP60 on the brain in vivo.
Results We show here that HSP60 injected intrathecally causes neuronal and
oligodendrocyte injury in the CNS in vivo through TLR4-dependent signaling.
Intrathecal HSP60 results in neuronal cell death, axonal injury, loss of
oligodendrocytes, and demyelination in the cerebral cortex of wild-type mice.
In contrast both mice lacking TLR4 and the TLR adaptor molecule MyD88 are
protected against deleterious effects induced by HSP60. In contrast to the
exogenous TLR4 ligand, lipopolysaccharide, intrathecal HSP60 does not induce
such a considerable inflammatory response in the brain. In the CNS, endogenous
HSP60 is predominantly expressed in neurons and released during brain injury,
since the cerebrospinal fluid (CSF) from animals of a mouse stroke model
contains elevated levels of this stress protein compared to the CSF of sham-
operated mice. Conclusions Our data show a direct toxic effect of HSP60
towards neurons and oligodendrocytes in the CNS. The fact that these harmful
effects involve TLR4 and MyD88 confirms a molecular pathway mediated by the
release of endogenous TLR ligands from injured CNS cells common to many forms
of brain diseases that bi-directionally links CNS injury and activation of the
innate immune system to neurodegeneration and demyelination in vivo
Early detection of brain metastases in a supervised exercise program for patients with advanced breast cancer : A case report
Introduction
Around 25% of metastatic breast cancer (mBC) patients develop brain metastases, which vastly affects their overall survival and quality of life. According to the current clinical guidelines, regular magnetic resonance imaging screening is not recommended unless patients have recognized central nervous system–related symptoms.
Patient Presentation
The patient participated in the EFFECT study, a randomized controlled trial aimed to assess the effects of a 9-month structured, individualized and supervised exercise intervention on quality of life, fatigue and other cancer and treatment-related side effects in patients with mBC. She attended the training sessions regularly and was supervised by the same trainer throughout the exercise program. In month 7 of participation, her exercise trainer detected subtle symptoms (e.g., changes in movement pattern, eye movement or balance), which had not been noticed or reported by the patient herself or her family, and which were unlikely to have been detected by the oncologist or other health care providers at that point since symptoms were exercise related. When suspicion of brain metastases was brought to the attention of the oncologist by the exercise trainer, the response was immediate, and led to early detection and treatment of brain metastases.
Conclusion and clinical implications
The brain metastases of this patient were detected earlier due to the recognition of subtle symptoms detected by her exercise trainer and the trust and rapid action by the clinician. The implementation of physical exercise programs for cancer patients requires well-trained professionals who know how to recognize possible alterations in patients and also, good communication between trainers and the medical team to enable the necessary actions to be taken
Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis
RAS-signaling mutations induce the myelomonocytic differentiation and proliferation of hematopoietic stem and progenitor cells. Moreover, they are important players in the development of myeloid neoplasias. RAF kinase inhibitor protein (RKIP) is a negative regulator of RAS-signaling. As RKIP loss has recently been described in RAS-mutated myelomonocytic acute myeloid leukemia, we now aimed to analyze its role in myelomonocytic differentiation and RAS-driven leukemogenesis. Therefore, we initially analyzed RKIP expression during human and murine hematopoietic differentiation and observed that it is high in hematopoietic stem and progenitor cells and lymphoid cells but decreases in cells belonging to the myeloid lineage. By employing short hairpin RNA knockdown experiments in CD34+ umbilical cord blood cells and the undifferentiated acute myeloid leukemia cell line HL-60, we show that RKIP loss is indeed functionally involved in myelomonocytic lineage commitment and drives the myelomonocytic differentiation of hematopoietic stem and progenitor cells. These results could be confirmed in vivo, where Rkip deletion induced a myelomonocytic differentiation bias in mice by amplifying the effects of granulocyte macrophage-colony-stimulating factor. We further show that RKIP is of relevance for RAS-driven myelomonocytic leukemogenesis by demonstrating that Rkip deletion aggravates the development of a myeloproliferative disease in NrasG12D-mutated mice. Mechanistically, we demonstrate that RKIP loss increases the activity of the RAS-MAPK/ERK signaling module. Finally, we prove the clinical relevance of these findings by showing that RKIP loss is a frequent event in chronic myelomonocytic leukemia, and that it co-occurs with RAS-signaling mutations. Taken together, these data establish RKIP as novel player in RAS-driven myeloid leukemogenesis
The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration
Background Toll-like receptors (TLRs) enable innate immune cells to respond to
pathogen- and host-derived molecules. The central nervous system (CNS)
exhibits most of the TLRs identified with predominant expression in microglia,
the major immune cells of the brain. Although individual TLRs have been shown
to contribute to CNS disorders, the consequences of multiple activated TLRs on
the brain are unclear. We therefore systematically investigated and compared
the impact of sole and pairwise TLR activation on CNS inflammation and injury.
Methods Selected TLRs expressed in microglia and neurons were stimulated with
their specific TLR ligands in varying combinations. Cell cultures were then
analyzed by immunocytochemistry, FlowCytomix, and ELISA. To determine neuronal
injury and neuroinflammation in vivo, C57BL/6J mice were injected
intrathecally with TLR agonists. Subsequently, brain sections were analyzed by
quantitative real-time PCR and immunohistochemistry. Results Simultaneous
stimulation of TLR4 plus TLR2, TLR4 plus TLR9, and TLR2 plus TLR9 in microglia
by their respective specific ligands results in an increased inflammatory
response compared to activation of the respective single TLR in vitro. In
contrast, additional activation of TLR7 suppresses the inflammatory response
mediated by the respective ligands for TLR2, TLR4, or TLR9 up to 24 h,
indicating that specific combinations of activated TLRs individually modulate
the inflammatory response. Accordingly, the composition of the inflammatory
response pattern generated by microglia varies depending on the identity and
combination of the activated TLRs engaged. Likewise, neuronal injury occurs in
response to activation of only selected TLRs and TLR combinations in vitro.
Activation of TLR2, TLR4, TLR7, and TLR9 in the brain by intrathecal injection
of the respective TLR ligand into C57BL/6J mice leads to specific expression
patterns of distinct TLR mRNAs in the brain and causes influx of leukocytes
and inflammatory mediators into the cerebrospinal fluid to a variable extent.
Also, the intensity of the inflammatory response and neurodegenerative effects
differs according to the respective activated TLR and TLR combinations used in
vivo. Conclusions Sole and pairwise activation of TLRs modifies the pattern
and extent of inflammation and neurodegeneration in the CNS, thereby enabling
innate immunity to take account of the CNS diseases’ diversity
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.
Although several lung cancer susceptibility loci have been identified, much of the heritability for lung cancer remains unexplained. Here 14,803 cases and 12,262 controls of European descent were genotyped on the OncoArray and combined with existing data for an aggregated genome-wide association study (GWAS) analysis of lung cancer in 29,266 cases and 56,450 controls. We identified 18 susceptibility loci achieving genome-wide significance, including 10 new loci. The new loci highlight the striking heterogeneity in genetic susceptibility across the histological subtypes of lung cancer, with four loci associated with lung cancer overall and six loci associated with lung adenocarcinoma. Gene expression quantitative trait locus (eQTL) analysis in 1,425 normal lung tissue samples highlights RNASET2, SECISBP2L and NRG1 as candidate genes. Other loci include genes such as a cholinergic nicotinic receptor, CHRNA2, and the telomere-related genes OFBC1 and RTEL1. Further exploration of the target genes will continue to provide new insights into the etiology of lung cancer
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie
Allocation techniques for balance at baseline in cluster randomized trials: a methodological review
- …